Aromatic heterocyclic compounds as anti-inflammatory agents

A compound of the formula (I):

• wherein:
• Ar1 is selected from the group consisting of pyrrole and thiophene;
• and wherein Ar1 may be substituted by one or more R1,R2 or R3;
• Ar2 is:
• naphthyl optionally substituted with one to three R10 groups;
• L is a C1-10 saturated or unsaturated branched or unbranched carbon chain;
• wherein one or more methylene groups are optionally independently replaced by O,N or S;
• wherein L is optionally independently substituted with 1-2 oxo groups or one or more C1-4 branched or unbranched alkyl which may be substituted by one or more halogen atoms;
• Q is selected from the group consisting of:
• a) pyrimidine, pyridazine which are optionally substituted with one to three groups selected from the group consisting of halogen, C1-6 alkyl, C1-6 alkoxy, hydroxy, mono- or di-(C1-3 alkyl)amino, C1-6 alkyl-S(O)m and phenylamino wherein the phenyl ring is optionally substituted with one to two groups selected from the group consisting of halogen, C1-6 alkyl and C1-6 alkoxy;
• b) morpholine, thiomorpholine, thiomorpholine sulfoxide and tetrahydropyrimidone, which are optionally substituted with one to three groups selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, hydroxy, mono- or di-(C1-3 alkyl)amino-C1-3 alkyl, phenylamino-C1-3 alkyl and C1-3 alkoxy-C1-3 alkyl;
• R1 is selected from the group consisting of:
• a) C3-10 branched or unbranched alkyl, which may optionally be partially or fully halogenated, and optionally substituted with one to three phenyl, naphthyl or heterocyclyl groups selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl and isothiazolyl;
• each such phenyl, naphthyl or heterocyclyl, selected from the group hereinabove described, being substituted with 1 to 5 groups selected from the group consisting of halogen, C1-6 branched or unbranched alkyl which is optionally partially or fully halogenated, C3-8 cycloalkyl, C5-8 cycloalkenyl, hydroxy, cyano, C1-3 alkoxy which is optionally partially or fully halogenated, NH2C(O) and di(C1-3)alkylaminocarbonyl;
• b) C3-7 cycloalkyl selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl, bicyclohexanyl and bicycloheptanyl, which may optionally be partially or fully halogenated and which may optionally be substituted with one to three C1-3 alkyl groups, or an analog of such cycloalkyl group wherein one to three ring methylene groups are replaced by groups independently selected from O, S, CHOH, >C═O, >C═S and NH;
• c) C3-10 branched alkenyl which may optionally be partially or fully halogenated, and which optionally be substituted with one to three C-1-5 branched or unbranched alkyl, phenyl, naphthyl or heterocyclyl groups, with each such heterocyclyl group being independently selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl and isothiazolyl, and each such phenyl, naphthyl or heterocyclyl group being substituted with 1 to 5 groups selected from halogen, C1-6 branched or unbranched alkyl which is optionally partially or fully halogenated, cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl, bicyclohexanyl and bicycloheptanyl, hydroxy, cyano, C1-3 alkoxy which is optionally partially or fully halogenated, NH2C(O) and mono- or di(C1-3)alkylaminocarbonyl;
• d) C5-7 cycloalkenyl selected from the group consisting of cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, bicyclohexenyl and bicycloheptenyl, wherein such cycloalkenyl group may optionally be substituted with one to three C1-3 alkyl groups;
• e) cyano;
• and,
• f) methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl;
• R2 is selected from the group consisting of:
• hydrogen, C1-6 branched or unbranched alkyl which may optionally be partially or fully halogenated, acetyl, aroyl, C1-4 branched or unbranched alkoxy which may optionally be partially or fully halogenated, halogen, methoxycarbonyl and phenylsulfonyl;
• R3 is:
• halogen, —COOR4, —CN, —CONR5R6 or —CH2NHR7;
• R4 is hydrogen or C1-4-alkyl;
• R5 is hydrogen;
• R6 is methyl;
• R7 is hydrogen, methyl or —C(O)R8;
• R8 is hydrogen or methyl optionally substituted by N(R9)2 or COOR9;
• R9 is C1-6-alkyl;
• R10 is selected from the group consisting of:
• a C1-6 branched or unbranched alkyl which may optionally be partially or fully halogenated, acetyl, aroyl, C1-4 branched or unbranched alkoxy which may optionally be partially or fully halogenated, halogen, methoxycarbonyl and phenylsulfonyl;
• m is 0, 1 or2;
• and
• X is O or S or
• the pharmaceutically acceptable salts, esters, isomers and mixtures of isomers thereof.